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Abstract
Background: Dual bronchodilator therapy is recommended for symptomatic patients with chronic obstructive
pulmonary disease (COPD). There are limited data on effects of a combination of two long-acting bronchodilators
on lung function including body plethysmography.
Methods: This multicentre, randomised, double-blind, single-dose, cross-over, placebo-controlled study evaluated
efficacy and safety of the free combination of indacaterol maleate (IND) and glycopyrronium bromide (GLY) versus
IND alone on spirometric and body plethysmography parameters, including inspiratory capacity (IC), forced
expiratory volume in 1 s (FEV1), forced vital capacity (FVC), total lung capacity (TLC) and airway resistance (Raw)
in moderate-to-severe COPD patients.
Results: Seventy-eight patients with FEV1 % pred. (mean ± SD) 56 ± 13% were randomised. The combination of
IND + GLY versus IND presented a numerically higher peak-IC (Δ = 0.076 L, 95% confidence interval [CI]: −0.010 – 0.161 L;
p = 0.083), with a statistically significant difference in mean IC over 4 h (Δ = 0.054 L, 95%CI 0.022 – 0.086 L; p = 0.001).
FEV1, FVC and Raw, but not TLC, were consistently significantly improved by IND + GLY compared to IND alone. Safety
profiles of both treatments were comparable.
Conclusion: The free combination of IND + GLY improved lung function parameters as evaluated by spirometry and
body plethysmography, with a similar safety profile compared to IND alone.
Trial registration: NCT01699685
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Background
Static lung hyperinflation is one of the significant chal-
lenges in patients with COPD. It is characterised by a
decrease in the elastic recoil of the lungs with a prema-
ture closure of small airways leading to air trapping. The
impact on lung function parameters is expressed by an
increase in functional residual capacity (FRC) and a
progressive decrease in inspiratory reserve volume and
inspiratory capacity (IC). During exercise, dynamic
compression of the airways intensifies and this results
in increased dynamic hyperinflation, leading to further
exercise limitation [1]. The major clinically relevant
mechanism of action of long-acting bronchodilators in
COPD is related to the reduction of hyperinflation [1–5],
which can be assessed by improvements in IC [6].
Whereas short-acting bronchodilators are used for im-
mediate relief from symptoms, one or more long-acting
bronchodilators (long-acting β2-agonists [LABAs], e.g.,
indacaterol maleate [IND], and long-acting muscarinic
antagonists [LAMAs], e.g., glycopyrronium bromide
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[GLY]) are recommended for long-term maintenance
therapy in patients with moderate-to-severe COPD [7].
Since LABAs and LAMAs have different mechanisms
of action, they may exert additive bronchodilation ef-
fects when used together. This suggests that IND and
GLY could be used in combination to optimise and
maximise bronchodilation in patients with COPD
whose needs are not adequately met by LABA or
LAMA monotherapy [8–10]. However, there are limited
data on the effects of a combination of two long-acting
bronchodilators on body plethysmography lung function
parameters in patients with COPD [11].
In this study we evaluated the efficacy and safety of
the free combination of IND + GLY versus IND alone on
lung function parameters evaluated by body plethysmog-
raphy, including inspiratory capacity (IC), forced expira-
tory volume in 1 s (FEV1), forced vital capacity (FVC),
total lung capacity (TLC) and airway resistance (Raw), in
patients with moderate-to-severe COPD.
Methods
Study population
The study was conducted in 11 centres in Switzerland
between November 2012 and June 2014, and included a
total of 78 eligible patients who were randomised to one
of two treatment sequences. The study protocol was
reviewed and approved by institutional review boards
and ethics committees.
Eligible patients were adults aged ≥40 years with a
diagnosis of moderate or severe COPD according to
GOLD criteria [12] who had signed an informed consent
form, and fulfilling the following: smoking history of at
least 10 pack-years [both current and ex-smokers];
post-bronchodilator FEV1 <80% and ≥30% of the pre-
dicted value, and post-bronchodilator FEV1/FVC <70%.
The main exclusion criteria were COPD exacerbations
requiring systemic glucocorticoid treatment or antibi-
otics and/or hospitalisation or a history of respiratory
tract infection within 6 weeks prior to screening, con-
comitant pulmonary disease other than COPD, history
of asthma or lung cancer, a known history of alpha-1
antitrypsin deficiency, or a history of hypersensitivity to
any of the study medications or to medications from
similar drug classes.
Study design and treatment
This was a multicentre, randomised, double-blind, single-
dose, cross-over, placebo-controlled study to assess the
effect of a single-dose combination of inhaled IND
(150 μg) + GLY (50 μg) versus inhaled IND (150 μg) +
placebo (corresponding GLY placebo) on static hyperin-
flation (Fig. 1). Patients had lung function assessments
(spirometry) at each study visit and body plethysmogra-
phy at Visits 2 and 3. Safety assessments included
physical examinations, vital signs, and monitoring of
adverse events (AEs) and serious adverse events (SAEs).
All patients prematurely withdrawing from the study
underwent study completion evaluations.
Study objectives
The primary objective was to demonstrate superiority of
a single dose of the combined inhalation of IND +GLY
versus IND alone on peak-IC, defined as the maximum
value within 4 h of inhalation. The key secondary objective
was to compare the efficacy of IND +GLY versus IND in
terms of FEV1 over 4 h (30, 60, 120, 180 and 240 min)
post dosing. Other secondary objectives were to compare
the efficacy of IND +GLY versus IND on IC, FVC, and
airway resistance (Raw) over 4 h (30, 60, 120, 180 and
240 min) after dosing.
Statistical analysis
Sample size calculation
With regard to peak-IC, a sample size of 69 patients
was expected to provide 80% power to detect a differ-
ence of 0.12 L in IC at peak between the groups, as-
suming a standard deviation of differences of 0.35 L
(test level α = 0.025 one-sided or α = 0.05 two-sided).
Assuming a dropout rate of approximately 10%, a total
of ~78 patients had to be randomised to ensure that at
least 70 patients completed the study. Regarding FEV1,
a sample size of 70 patients provided 99% power to de-
tect a difference of 0.18 L in FEV1 mean values between
the groups.
The intention to treat (ITT, full analysis set [FAS]) popu-
lation consisted of all randomised patients who received at
least one dose of study medication and had at least one
post-baseline assessment of the primary efficacy variable.
The per-protocol (PP) population consisted of all patients
in the ITT population without major protocol violations or
who discontinued the study due to treatment-related rea-
sons. A supportive analysis on the PP population was per-
formed for the primary endpoint peak-IC and the key
secondary endpoint FEV1. The safety population (full
Randomisation
Treatment
Visit 2
Treatment
Visit 3
IND + placebo
IND + GLY IND + GLY
IND + placebo
Day 0 Day 6 (+4)Day -10
to
Day -1
Day 1
to
Day 5
30 days
after
Visit 3
Wash-out Safety 
follow up
IND, indacaterol; GLY, glycopyrronium
Fig. 1 Study design
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analysis set; FAS) was defined as all randomised pa-
tients who received at least one dose of study medica-
tion with at least one post-baseline safety assessment.
Study endpoints were analysed by an analysis of co-
variance (ANCOVA) model with treatment sequence
(AB or BA) and treatment as fixed effects, the lung func-
tion parameter as a covariate and patient as a random
effect. Treatment effect was estimated as the contrast of
the treatment effect in the statistical model and pre-
sented as point estimates and corresponding 95% two-
sided confidence intervals (CIs). The null hypothesis for
the primary analysis was that combination of IND +GLY
is not superior to IND alone regarding the lung function
parameters. The alternative hypothesis was that treat-
ment with a combination of IND +GLY is superior to
IND alone. The null hypothesis was rejected in favour of
the alternative hypothesis if the 95% CI of the least
squares means treatment contrast of the difference
“combination therapy — single therapy” was greater
than 0 in its entirety. This corresponds to a planned
alpha error of 5% two-sided or 2.5% one-sided. An
interim analysis was performed after 20 patients had
completed Visit 3. No adjustments were needed.
Results
The mean ± SD age of the patients was 64.8 ± 8.4 years
(Table 1), 59.2% were male, all Caucasian, and 24
(31.2%) current smokers. Mean time since COPD diag-
nosis was 5.2 ± 5.2 years. The mean FEV1% predicted
was 56 ± 13 and 38.7% of patients had a GOLD stage of
III or above. The mean total lung capacity (TLC) was
120.68 ± 18.75% pred. and the mean Raw was 210.99 ±
117.11% pred. The patient disposition and randomisa-
tion is given in Fig. 2.
The combination of IND +GLY versus IND presented
a numerically higher peak-IC (2.95 L versus 2.88 L), with
an adjusted treatment difference (Δ) of 0.076 L (95%
−0.010 – 0.161 L; p = 0.083) (Fig. 3a). IND +GLY pre-
sented also a statistically significant difference in mean
IC over 4 h versus IND (2.76 L versus 2.70 L; Δ =
0.054 L, 95% CI 0.022 – 0.086 L; p = 0.001) (Fig. 3b).
FEV1, FVC and Raw, but not TLC, were significantly im-
proved by IND +GLY compared to IND alone. A statisti-
cally significant adjusted treatment difference in FEV1
was noted at all time points in favour of IND +GLY
treatment (p <0.001 for all comparisons), reaching a peak
difference of Δ = 0.099 L (95%CI 0.060 – 0.139 L) at
120 min post-dose (Fig. 4a). Similarly, IND +GLY re-
sulted in higher FVC mean values at all time points after
a single-dose inhalation (p <0.01 for all comparisons),
reaching a peak difference of Δ = 0.163 L (95%CI 0.092 –
0.234 L) at 240 min post-dose (Fig. 4b). Raw measure-
ments were consistently lowered by IND + GLY treat-
ment at all time points after the single-dose inhalation
(p <0.001 for all comparisons), reaching a peak difference
of Δ = -0.667 cmH2O/L/sec (95%CI -0.928 – -0.406
cmH2O/L/sec) at 240 min post-dose (Fig. 4c), in favour
of dual bronchodilation (p ≤0.001). There were no differ-
ences in TLC between the study treatments.
Safety
Eight (10.4%) patients experienced treatment-emergent
adverse events (TEAEs) (Table 2). No patient died in the
course of the study or experienced any treatment-emer-
gent SAE. According to the investigators’ assessment, a
relation to study medication was not suspected for any
of the TEAEs. The intensity of TEAEs was mostly mild
Table 1 Demography and baseline characteristics (ITT population,
N = 76)
Mean (SD), N = 76
Age at informed consent, years 64.80 (8.39)
Height, cm 168.22 (8.55)
Weight, kg 75.45 (15.52)
BMI, kg/m2 26.65 (5.05)
Smoking history
Number of pack-years, years
50.13 (23.28)
Years since COPD diagnosis 5.17 (5.24)
Age at COPD diagnosis, years 60.16 (10.96)
FEV1 % predicted 56.09 (13.28)
FEV1*, L 1.50 (0.45)
FVC*, L 2.95 (0.89)
IC, L 2.45 (0.69)
Total Lung Capacity (TLC), L 7.13 (1.42)
TLC % of predicted normal value 120.68 (18.75)
Airway Resistance (Raw) 6.73 (3.19)
Raw % of predicted normal value 210.99 (117.11)
Hyperinflation IC/TLC 0.35 (0.09)
N (%)
Gender Male 45 (59.2)
Female 31 (40.8)
Number of patients with
current medical condition
CAD 7 (9.2)
Hypertension 29 (38.2)
Diabetes mellitus 4 (5.3)
Number of patients
according COPD GOLD-stage
Stage I 8 (10.5)
Stage II 31 (40.8)
Stage III 30 (39.5)
Stage IV 7 (9.2)
ITT intention to treat, N/n number of patients, BMI body mass index, SD
standard deviation, COPD chronic obstructive pulmonary disease, FEV1 forced
expiratory volume in 1 s, FVC forced vital capacity, IC inspiratory capacity,
CAD coronary artery disease, GOLD stage defined as: stage I = FEV1/FVC <70%
and FEV1 ≥80% predicted; stage II = FEV1/FVC <70% and 50% ≤FEV1 <80%
predicted; stage III = FEV1/FVC <70% and 30% ≤FEV1 <50% predicted; stage
IV = FEV1/FVC <70% and FEV1 <30% predicted
*N = 75
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(6 patients) or moderate (2 patients). Prior to the first
dose of study medication, one patient experienced atrial
fibrillation of moderate intensity. In conclusion, the
treatments were well tolerated with a good safety
profile.
Discussion
In this prospective, randomised study we showed that
the combination of two long-acting bronchodilators pro-
vided a greater improvement in lung hyperinflation and
lung function parameters compared to a single long-act-
ing agent. Specifically, IND +GLY provided a numerical
improvement in peak-IC combined with a statistically sig-
nificant difference in mean IC over 4 h compared to
IND monotherapy. Additionally, the treatment with
IND + GLY resulted in consistent statistically significant
improvements in FEV1, FVC and Raw compared to
IND alone. The two treatments presented a similar
safety profile.
As a unique feature of the trial, the use of body pleth-
ysmography allowed us to observe the significant differ-
ence in Raw in favour for IND +GLY in this study. Raw
is not frequently reported in studies evaluating the effect
of bronchodilators in COPD. However, this parameter
is suggested to be sensitive and to reflect airflow ob-
struction, particularly of the peripheral airways, more
accurately than the FEV1/FVC ratio. In assessing the
acute functional effect of bronchodilators, specific Raw
change-based criteria may be preferable to FEV1- or
FVC-based criteria, being more closely related to
bronchodilator-induced improvements in lung mechan-
ics and dyspnoea at rest [13]. Raw measurements were
strongly improved by IND + GLY treatment compared
to IND monotherapy at all time points after single-dose
inhalation.
A possible explanation of the non-statistically significant
result in SYNERGY on peak-IC might be attributed to the
high variability of this measurement. This is supported by
the fact that in contrast to the peak-IC measurement, the
adjusted mean IC in the SYNERGY study (which included
several values) presented a statistically significant differ-
ence between the two treatments. Additionally, the results
of the present study are consistent with those of other
published studies that have investigated the efficacy and
safety of LABA/LAMA combination therapy in patients
with COPD [7, 11, 14–18]. In order to allow for higher
power and better generalisability of the results, we add-
itionally evaluated with a similar analysis as in SYNERGY
the peak-IC and FEV1 in a pooled analysis of patient-level
data (n = 1,548) from 3 studies that evaluated the combin-
ation of IND +GLY versus IND, i.e. SYNERGY (present
study), SHINE [14] and GLOW6 [7] (see details in the
Additional file 1 Online Supplement). Mean adjusted
peak-IC in this pooled analysis was statistically signifi-
cantly higher for patients treated with IND +GLY versus
IND alone (Δ = 0.075 L; 95% CI 0.040 – 0.109 L; p ≤0.001)
(Additional file 2 Figure S1). Additionally, FEV1 was sta-
tistically significantly higher for IND + GLY versus IND
at 30, 120 and 240 min after a single dose inhalation,
with a maximal difference at 120 min (Δ = 0.094 L; 95%
99 patients registered (= Total set)
21 screening failures
78 patients undergoing randomization
1 patient received
no medication
39 assigned to
Sequence A
1 without post-baseline
efficacy data
38 FAS
35 PP 34 PP
0 did not complete treatment
0 did not complete follow-up
4 other protocol deviations
0 did not complete treatment
0 did not complete follow-up
3 other protocol deviations
38 FAS
0 without post-baseline
efficacy data
38 assigned to
Sequence B
77 Safety
FAS, full analysis set; PP, Per protocol set
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CI 0.076 – 0.112 L; p ≤0.001) (Additional file 3 Figure S2).
These results further support the reduction of static
hyperinflation, as expressed by IC, by a combination of
two bronchodilators compared to a single agent.
The physiological and clinical significance of these
results can be attributed to prolonged maximal bron-
chodilation that minimises air trapping and leads to
effective reduction of static and dynamic lung
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Salomon et al. Respiratory Research  (2017) 18:13 Page 5 of 7
hyperinflation. Improved IC is associated with improved
exercise endurance and dyspnoea [2, 3] and potentially
improved long-term outcomes. Casanova et al. showed
that lung hyperinflation, as expressed by the IC/TLC ratio,
is an independent predictor of mortality [19]. Further-
more, Tantucci et al. identified IC as a powerful functional
predictor of all-cause and respiratory mortality and of
exacerbation-related hospital admissions in patients
with COPD [20].
The improvement in bronchodilation and measures of
hyperinflation observed in the present study is supported
by data from the BRIGHT study (IND/GLY fixed-dose
combination versus placebo and tiotropium), which
showed significantly improved dynamic IC, trough
FEV1, residual volume (RV) and FRC in patients with
moderate-to-severe COPD receiving IND/GLY that
were accompanied by increased exercise endurance
[11]. Mahler et al. showed that IND + tiotropium provided
greater bronchodilation and lung deflation compared with
tiotropium monotherapy [17]. To what extent these ef-
fects have a clinically significant impact on outcomes
other than lung function and exercise endurance requires
further evaluation. However, there is significant evidence
that exacerbations, the relevant trigger for progression,
are more effectively prevented by IND +GLY than by a
single long-acting bronchodilator [21].
We acknowledge that there were limitations in the
study. These include the cross-over study design, the
short study duration, and the potentially limited patient
population due to the clinical trial settings. Additionally,
we need to acknowledge that in patients with severe
airflow limitation, the plethysmographic Raw may be of
limited validity. Finally, post hoc it became obvious that
possibly the initially taken assumptions for the power
calculations were overestimated, resulting in a relatively
small sample size to reach statistical significance. This is
supported by the results of the pooled analysis showing
the statistical significance for peak-IC.
In our study all treatments were equally well tolerated
and showed a good safety profile, which is also docu-
mented in multiple clinical trials and the use in clinical
practice [7, 8, 10, 11, 14, 16, 17, 21].
Conclusions
In summary, the results of the present study show that
treatment with IND + GLY had a stronger beneficial
effect on lung hyperinflation and airflow obstruction
parameters in patients with COPD than treatment
with IND alone. The treatment was well tolerated and
had a good safety profile. These data support the use
of dual bronchodilator therapy to not only improve
airway calibre (FEV1) but also decrease hyperinflation
and its associated negative consequences in patients
with COPD.
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